Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

(2019) Abdul Rafeh Naqash et al.   Journal for ImmunoTherapy of Cancer

Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors

(2019) Inbar Finkel et al.   JOURNAL OF IMMUNOTHERAPY

A case of severe Pembrolizumab-induced neutropenia

(2018) Barbacki Ariane et al.   ANTI-CANCER DRUGS

Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma

(2018) Adam R Bryant et al.   BONE MARROW TRANSPLANTATION

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy

(2018) Yamin Sun et al.   JOURNAL OF IMMUNOTHERAPY

Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma

(2018) Kentaro Tokumo et al.   LUNG CANCER

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies

(2018) Jiang-Dong Sui et al.   Drug Design Development and Therapy

Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression

(2018) Nicholas Meti et al.   Journal of Oncology Practice

Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis

(2018) Fausto Petrelli et al.   EUROPEAN JOURNAL OF CANCER

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

(2018) Arabella Young et al.   Cancer Immunology Research

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

(2018) Nicolas Delanoy et al.   Lancet Haematology

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab

(2018) Ayumu Takahashi et al.   INTERNAL MEDICINE

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

(2017) Sébastien Le Burel et al.   EUROPEAN JOURNAL OF CANCER

Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study

(2017) Chor-Wing Sing et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia

(2017) Chao Liu et al.   Therapeutics and Clinical Risk Management

Nivolumab-induced aplastic anemia: A case report and literature review

(2017) Rachel R Comito et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab

(2016) Samer Tabchi et al.   LUNG CANCER

Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice

(2016) Jan Gaertner et al.   PALLIATIVE MEDICINE

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Treatment of PD-1−/−mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients

(2015) Imir G. Metushi et al.   HEPATOLOGY

Toxicity Patterns With Immunomodulating Antibodies and Their Combinations

(2015) John B.A.G. Haanen et al.   SEMINARS IN ONCOLOGY

Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report

(2015) Sebastian Woźniak et al.   Oncology Research and Treatment

Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case–Control Surveillance Study

(2014) Matthias Huber et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis

(2014) Alexander Johnston et al.   Expert Opinion on Drug Metabolism & Toxicology

Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma

(2014) Pauline du Rusquec et al.   JOURNAL OF IMMUNOTHERAPY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunology beats cancer: a blueprint for successful translation

(2012) Drew M Pardoll   NATURE IMMUNOLOGY

Clinical presentation and management of drug-induced agranulocytosis

(2011) Emmanuel Andrès et al.   Expert Review of Hematology

Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)

(2009) Mojtaba Akhtari et al.   JOURNAL OF IMMUNOTHERAPY